Literature DB >> 25038828

Huntington's disease is a four-repeat tauopathy with tau nuclear rods.

Marta Fernández-Nogales1, Jorge R Cabrera2, María Santos-Galindo2, Jeroen J M Hoozemans3, Isidro Ferrer4, Annemieke J M Rozemuller3, Félix Hernández1, Jesús Avila1, José J Lucas1.   

Abstract

An imbalance of tau isoforms containing either three or four microtubule-binding repeats causes frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) in families with intronic mutations in the MAPT gene. Here we report equivalent imbalances at the mRNA and protein levels and increased total tau levels in the brains of subjects with Huntington's disease (HD) together with rod-like tau deposits along neuronal nuclei. These tau nuclear rods show an ordered filamentous ultrastructure and can be found filling the neuronal nuclear indentations previously reported in HD brains. Finally, alterations in serine/arginine-rich splicing factor-6 coincide with tau missplicing, and a role of tau in HD pathogenesis is evidenced by the attenuation of motor abnormalities of mutant HTT transgenic mice in tau knockout backgrounds.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25038828     DOI: 10.1038/nm.3617

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  26 in total

1.  Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease.

Authors:  A Yamamoto; J J Lucas; R Hen
Journal:  Cell       Date:  2000-03-31       Impact factor: 41.582

2.  Isoforms changes of tau protein during development in various species.

Authors:  Hiroshi Takuma; Shigeki Arawaka; Hiroshi Mori
Journal:  Brain Res Dev Brain Res       Date:  2003-05-14

3.  Developmentally regulated expression of specific tau sequences.

Authors:  K S Kosik; L D Orecchio; S Bakalis; R L Neve
Journal:  Neuron       Date:  1989-04       Impact factor: 17.173

4.  Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.

Authors:  L Mangiarini; K Sathasivam; M Seller; B Cozens; A Harper; C Hetherington; M Lawton; Y Trottier; H Lehrach; S W Davies; G P Bates
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

5.  Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) modulates serine/arginine-rich protein 55 (SRp55)-promoted Tau exon 10 inclusion.

Authors:  Xiaomin Yin; Nana Jin; Jianlan Gu; Jianhua Shi; Jianhua Zhou; Cheng-Xin Gong; Khalid Iqbal; Inge Grundke-Iqbal; Fei Liu
Journal:  J Biol Chem       Date:  2012-07-05       Impact factor: 5.157

6.  Similarities between spinocerebellar ataxia type 7 (SCA7) cell models and human brain: proteins recruited in inclusions and activation of caspase-3.

Authors:  C Zander; J Takahashi; K H El Hachimi; H Fujigasaki; V Albanese; A S Lebre; G Stevanin; C Duyckaerts; A Brice
Journal:  Hum Mol Genet       Date:  2001-10-15       Impact factor: 6.150

7.  Identification of oligomers at early stages of tau aggregation in Alzheimer's disease.

Authors:  Cristian A Lasagna-Reeves; Diana L Castillo-Carranza; Urmi Sengupta; Jose Sarmiento; Juan Troncoso; George R Jackson; Rakez Kayed
Journal:  FASEB J       Date:  2012-01-17       Impact factor: 5.191

8.  Correction of tau mis-splicing caused by FTDP-17 MAPT mutations by spliceosome-mediated RNA trans-splicing.

Authors:  Teresa Rodriguez-Martin; Karen Anthony; Mariano A Garcia-Blanco; S Gary Mansfield; Brian H Anderton; Jean-Marc Gallo
Journal:  Hum Mol Genet       Date:  2009-06-04       Impact factor: 6.150

Review 9.  Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies.

Authors:  Kurt R Brunden; John Q Trojanowski; Virginia M-Y Lee
Journal:  Nat Rev Drug Discov       Date:  2009-10       Impact factor: 84.694

10.  Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice.

Authors:  H N Dawson; A Ferreira; M V Eyster; N Ghoshal; L I Binder; M P Vitek
Journal:  J Cell Sci       Date:  2001-03       Impact factor: 5.285

View more
  92 in total

Review 1.  The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel therapeutic approaches.

Authors:  Elisabeth Daguenet; Gwendal Dujardin; Juan Valcárcel
Journal:  EMBO Rep       Date:  2015-11-13       Impact factor: 8.807

Review 2.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-24       Impact factor: 3.575

3.  Spleen tyrosine kinase (SYK) blocks autophagic Tau degradation in vitro and in vivo.

Authors:  Jonas Elias Schweig; Hailan Yao; Kyle Coppola; Chao Jin; Fiona Crawford; Michael Mullan; Daniel Paris
Journal:  J Biol Chem       Date:  2019-07-19       Impact factor: 5.157

4.  Profiling of Argonaute-2-loaded microRNAs in a mouse model of frontotemporal dementia with parkinsonism-17.

Authors:  Aidan Kenny; Félix Hernández; Jesús Avila; José J Lucas; David C Henshall; Jochen Hm Prehn; Eva M Jiménez-Mateos; Tobias Engel
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2018-12-25

Review 5.  RETRACTED ARTICLE: Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours.

Authors:  Fei Xu; Lixin Na; Yanfei Li; Linjun Chen
Journal:  Cell Biosci       Date:  2020-04-01       Impact factor: 7.133

Review 6.  Amyloidogenesis of Tau protein.

Authors:  Bartosz Nizynski; Wojciech Dzwolak; Krzysztof Nieznanski
Journal:  Protein Sci       Date:  2017-09-13       Impact factor: 6.725

7.  Tau Accumulation via Reduced Autophagy Mediates GGGGCC Repeat Expansion-Induced Neurodegeneration in Drosophila Model of ALS.

Authors:  Xue Wen; Ping An; Hexuan Li; Zijian Zhou; Yimin Sun; Jian Wang; Lixiang Ma; Boxun Lu
Journal:  Neurosci Bull       Date:  2020-06-04       Impact factor: 5.203

8.  Pazopanib Reduces Phosphorylated Tau Levels and Alters Astrocytes in a Mouse Model of Tauopathy.

Authors:  Monica Javidnia; Michaeline L Hebron; Yue Xin; Nikolas G Kinney; Charbel E-H Moussa
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 9.  Faulty RNA splicing: consequences and therapeutic opportunities in brain and muscle disorders.

Authors:  Vittoria Pagliarini; Piergiorgio La Rosa; Claudio Sette
Journal:  Hum Genet       Date:  2017-04-22       Impact factor: 4.132

Review 10.  Interactions Between α-Synuclein and Tau Protein: Implications to Neurodegenerative Disorders.

Authors:  Xuling Li; Simon James; Peng Lei
Journal:  J Mol Neurosci       Date:  2016-09-15       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.